On March 15, 2018 Incyte Corporation (Nasdaq:INCY) reported that 15 abstracts from its research and development portfolio will be presented at the upcoming 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting in Chicago, Illinois from April 14-18, 2018 (Press release, Incyte, MAR 15, 2018, View Source;p=RssLanding&cat=news&id=2338255 [SID1234524809]). These abstracts include the first pre-clinical data from the Company’s recently announced AXL/MER, TIM-3 and LAG-3 antibody programs in patients with advanced solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to present a broad collection of abstracts from our robust development portfolio at this year’s AACR (Free AACR Whitepaper) Annual Meeting," said Reid Huber, Ph.D., Incyte’s Chief Scientific Officer. "The acceptance of these abstracts and their results represent the progress Incyte continues to make in the pursuit of R&D excellence and ultimately innovation in the treatment of cancer and other serious diseases."

Key abstracts include:

Immuno-Therapy

Combination of a T Cell Activating Immunotherapy with Immune Modulators Alters the Tumor Microenvironment and Promotes More Effective Tumor Control in Preclinical Models (Abstract #1761, Immunology – Modifiers of the Tumor Microenvironment 2)

Monday, April 16, 2018, 8:00 a.m. – 12:00 p.m. CDT, Chicago, Poster Section 33
Identification of p-AKT as a PD marker for MER Kinase in Human G361 Cells (Abstract #2367, Molecular and Cellular Biology/Genetics – Kinases and Phosphatases)

Monday, April 16, 2018, 1:00 p.m. – 5:00 p.m. CDT, Chicago, Poster Section 17
Characterization of INCB081776, a Potent and Selective Dual AXL/MER Kinase Inhibitor (Abstract #3759, Immunology – Immunomodulatory Agents and Interventions 1)

Tuesday, April 17, 2018, 8:00 a.m. – 12:00 p.m. CDT, Chicago, Poster Section 32
INCAGN02390, a Novel Antagonist Antibody that Targets the Co-Inhibitory Receptor TIM-3 (Abstract #3825, Immunology – Therapeutic Antibodies, Including Engineered Antibodies 3)

Tuesday, April 17, 2018, 8:00 a.m. – 12:00 p.m. CDT, Chicago, Poster Section 34
INCAGN02385 is an Antagonist Antibody Targeting the Co-Inhibitory Receptor LAG-3 for the Treatment of Human Malignancies (Abstract #3819, Immunology – Therapeutic Antibodies, Including Engineered Antibodies 3)

Tuesday, April 17, 2018, 8:00 a.m. – 12:00 p.m. CDT, Chicago, Poster Section 34
Epacadostat plus Durvalumab in Patients with Advanced Solid Tumors: Preliminary Results of the Ongoing, Open-Label, Phase 1/2 ECHO-203 Study (Abstract #CT177, Session CTMS03 – Biomarkers in Immuno-Oncology [minisymposium])

Tuesday, April 17, 2018, 2:45 p.m. – 5:00 p.m. CDT, Chicago, N Hall C – McCormick Place North (Level 1)
Targeted Therapy

INCB052793, a JAK1 Selective Inhibitor, is Highly Efficacious in PDX and Xenograft Models of Acute Myeloid Leukemia (AML) Expressing Elevated Endogenous pSTAT3/pSTAT5 (Abstract #1867, Experimental and Molecular Therapeutics – Experimental Agents and Combinations for Hematologic Malignancies 2)

Monday, April 16, 2018, 8:00 a.m. – 12:00 p.m. CDT, Chicago, Poster Section 38
The Evaluation of INCB059872, an FAD-directed Inhibitor of LSD1, in Preclinical Models of T-ALL (Abstract #1893, Experimental and Molecular Therapeutics – Experimental Agents and Combinations for Hematologic Malignancies 2)

Monday, April 16, 2018, 8:00 a.m. – 12:00 p.m. CDT, Chicago, Poster Section 38
The FAD-directed LSD1 Specific Inhibitor, INCB059872, is a Promising Epigenetic Agent for AML Therapy by Inducing Differentiation of Leukemic Stem/Progenitor Cells (Abstract #1888, Experimental and Molecular Therapeutics – Experimental Agents and Combinations for Hematologic Malignancies 2)

Monday, April 16, 2018, 8:00 a.m. – 12:00 p.m. CDT, Chicago, Poster Section 38
INCB059872, a Novel FAD-directed LSD1 Inhibitor, is Active in Prostate Cancer Models and Impacts Prostate Cancer Stem-like Cells (Abstract #1379, Molecular and Cellular Biology/Genetics – Epigenetic Therapy)

Monday, April 16, 2018, 8:00 a.m. – 12:00 p.m. CDT, Chicago, Poster Section 16
In Vivo Assessment of the Combination of the JAK1-Selective Inhibitor Itacitinib with First- and Second-Generation EGFR Inhibitors in Models of Non-Small Cell Lung Cancer (Abstract #2938, Experimental and Molecular Therapeutics – Novel Experimental Combinations)

Monday, April 16, 2018, 1:00 p.m. – 5:00 p.m. CDT, Chicago, Poster Section 41
The FAD-Directed LSD1 Specific Inhibitor, INCB059872, Inhibits Cell Migration and Metastasis by Suppressing Premetastatic Niche Formation in a Spontaneous Metastasis Mouse Model (Abstract #3929, Experimental and Molecular Therapeutics – Resistance and Biology)

Tuesday, April 17, 2018, 8:00 a.m. – 12:00 p.m. CDT, Chicago, Poster Section 39
The BET Inhibitor INCB057643 Suppresses ALDH Activity by Targeting the ALDH1A1 Super-Enhancer in High-Grade Serous Ovarian Cancer (Abstract #3685, Clinical Research – Molecular Classification of Tumors 1: Epigenetic Therapy, Functional and Molecular Imaging, and Tumor Heterogeneity)

Tuesday, April 17, 2018, 8:00 a.m. – 12:00 p.m. CDT, Chicago, Poster Section 28
Effect of JAK/STAT or PI3Kδ Plus PD-1 Inhibition on the Tumor Microenvironment: Biomarker Results From a Phase 1b Study in Patients with Advanced Solid Tumors (Abstract #CT176, Session CTMS03 – Biomarkers in Immuno-oncology [minisymposium])

Tuesday, April 17, 2018, 2:45 p.m. – 5:00 p.m. CDT, Chicago, N Hall C – McCormick Place North (Level 1)
Anti-Tumor Efficacy of INCB057643, a Novel BET Bromodomain Inhibitor, in Castration-Resistant Prostate Cancer as Single Agent and in Combination Therapy (Abstract #5793, Experimental and Molecular Therapeutics – Canonical Targets 2)

Wednesday, April 18, 2018, 8:00 a.m. – 12:00 p.m. CDT, Chicago, Poster Section 36
Full session details and data presentation listings for AACR (Free AACR Whitepaper) 2018 can be found at: View Source!/4562